DOCSLIB.ORG

Activity Report 2016

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Activity Report 2016 Activity Report Edita: IDIVAL Depósito Legal: SA 525-2015 Valdecilla Biomedical Research Institute Avda. Cardenal Herrera Oria s/n 39011 Santander – Spain 05 Contents 07 Prologue 13 Valdecilla, IDIVAL 17 Organisational Structure 25 Researcher Support Services. 41 Training 55 Some milestones 2016 61 IDIVAL R&D Activity 93 Research Areas 95 Transplantation 119 Neuroscience 139 Cancer 173 Cross-Disciplinary 181 Infection and Immunity 207 Metabolism 07 Prologue 09 healthcare areas, whether in hospitals or in primary care, and researchers in biomedical and technological fields and other disciplines in our Autonomous Community, can and must be present in the projects designed to improve The Marqués de Valdecilla Research Institute (IDIVAL) healthcare in Cantabria. We believe that IDIVAL, like is established as a key actor in the generation of applied Valdecilla, must be both integrated and open, and have knowledge in our region. Its core engine, the Marqués the best among its personnel, in order to maintain a top- de Valdecilla University Hospital, one of Spain’s leading level healthcare system and continue to earn the support hospitals, in partnership with the University of Cantabria, of all Cantabria’s society. promotes new solutions for patients’ health problems thanks to the research and innovation of its excellent Similarly, we must continue working to ensure that the professionals. It is for this reason that we have the public-private partnership model, based on transparency, optimal elements to continue leading in certain fields of provides greater benefits. We must see the annual knowledge: expert personnel, next-generation technology expenditure of the healthcare sector in Cantabria as and magnificent facilities, which we are committed to an investment, an opportunity, and make the most of making the best possible use of. our partnerships with business, understanding that we can add value to its products, acquiring them, but Every day, the world’s best healthcare centres generate also evaluating, improving and designing them. The wealth and solutions for patients through research and experience and expertise of our professionals must be innovation. Spain as a whole hopes to move forward given the maximum value. in this value model based on knowledge, a value that includes the application of the generated knowledge and Talent is one of the main keys to success. Training a socioeconomic benefit. Cantabria is no exception, and new generations, facilitating their professional growth, has some elements that make it possible and almost especially in research and innovation, and attracting necessary: its size, an important Hospital and University, expert professionals to help this ongoing regeneration and a high level of scientific expertise. Knowledge in process, are essential goals for ensuring that the high the healthcare field generates wealth in itself, as IDIVAL quality healthcare system we want continues to be demonstrates, insofar as it creates jobs and improves one of the distinguishing features of our Autonomous the approach to health problems. However, we still have Community. To do this, we must create mechanisms to a long way to go. The modern globalised world gives us overcome barriers, whether geographical, administrative, unique opportunities that stem from interdisciplinary, or sometimes cultural, requiring the collaboration of multinational partnerships, and taking advantage of them patients, healthcare professionals, managers, and society is a key part of developing projects with real impact. in general. IDIVAL, as a Healthcare Research Institute accredited by the Carlos III Health Institute, encouraging translational research and innovation as a foundation for improving patient care, must have an international outlook. This cross-border vision must coexist with a integrating vision that lets the different areas that could add value María Luisa Real González to healthcare research in Cantabria contribute to IDIVAL. Minister of Health of the Government of Cantabria Patients, nurses, doctors, and personnel from other President of the Board of IDIVAL 11 necessary tool for our researchers, and to restore our library to the place its history deserves. Finally, I would like to welcome the research groups who passed a tough he Marqués de Valdecilla Research Institute (IDIVAL) evaluation and have now joined IDIVAL. We all hope is responsible for promoting and managing our they settle in quickly. As an example of our commitment biomedical research. IDIVAL has been recognised by to inclusiveness, let me highlight the research groups the Carlos III Health Institute as a benchmark centre for in Nursing and Primary Care. In a small Autonomous research in Spain. Its main distinguishing features include Community like ours, it is only by working together the search for excellence and innovation, always focused (hospitals, primary care, university and private enterprise) on improving the health of our citizens. that we can continue moving forwards to attract resources and scientific talent. 2016 was a productive year for IDIVAL. Among its achievements, in 2016 IDIVAL produced nearly 500 indexed publications, with a very high average impact factor (3.89), and 30 articles published in journals with an impact factor higher than 10. It continued to attract external resources, with 80 competitive research projects and 175 open clinical trials. This is an important point, because it shows we are competitive and contributes to our sustainability, for example enabling us to increase the number of post-MIR contracts and grants to research groups. A significant figure was the record number of competitive research projects granted by the Carlos III Health Institute in the 2016 campaign. However, in an increasingly competitive environment, we must be aware that IDIVAL can only be sustainable and continue to expand if we consolidate repeated access to European projects. This must be one of our main challenges in the coming years. To conclude, I will comment on some of the initiatives developed specifically in IDIVAL in 2016 that we are particularly proud of. We launched the COLABORA campaign, designed to attract altruistic, transparent donations for research, something our region was clearly lacking. The “Santander Biomedical Lectures” were a success in lecturers and attendees, and I am sure they Julio Pascual have contributed to creating a vocation for research Managing Director of the Marqués de Valdecilla University among some of the many young people who enjoyed Hospital, member of the Board of Governors, and Chairman of them. During 2016 the new website of the Marquesa the Executive Committee of the IDIVAL Board of Governors de Pelayo library was finalised. An extraordinary and 13 Valdecilla The innovative spirit of the Valdecilla Foundation and evolved following the mark is particularly evident in IDIVAL, model of health research institutes conceived with the goal of promoting and in line with the points set out R&D in the field of biomedical in Royal Decree 339/2004 of 27 Valdecilla is the unifying mark sciences at the Marqués de February. Therefore, the constitution that Ramón Pelayo de la Torriente, Valdecilla University Hospital with of IDIVAL implies strong support Marquis de Valdecilla left on the the contribution of the University of its founding institutions, the institutions that came to be during of Cantabria, placing it at a level of University of Cantabria and the his marquessate: the Marqués de national and international excellence. Government of Cantabria for health Valdecilla University Hospital, the research in the Valdecilla setting. de la Torriente, Marquis de Valdecilla IDIVAL was conceived at the end of left on the institutions that came to 2013 through an agreement between Taking over from IFIMAV, IDIVAL was be during his marquessate: the Government of Cantabria and the launched in 2014 to harmoniously the Marqués de Valdecilla University University of Cantabria, as the heir of integrate basic, clinical and public Hospital, the Marqués de Valdecilla the Marqués de Valdecilla Training health research, encouraging Research Institute (IDIVAL), and Research Institute (IFIMAV). translational research and promoting and the Valdecilla Virtual Hospital, a better transfer of the which today maintains the innovative, IFIMAV was established in 2002 scientific progress obtained in cross-disciplinary and philanthropic as a research management unit addressing the most prevalent health spirit with which it was created. within the Marqués de Valdecilla problems. 15 IDIVAL are also contributing to scientific IDIVAL seeks to improve translational production. research and promote progress in Cantabria. Its goals include IDIVAL promotes and manages the IDIVAL pursues excellence. In 2016, the development of knowledge, biomedical research of the Marqués IDIVAL’s researchers published high- technological progress, and de Valdecilla University Hospital impact works in collaboration with innovation in healthcare. IDIVAL’s and the University of Cantabria. some of the world’s best research current challenge is to maximise the It is financed by the Government groups in various biomedical application of research results to of Cantabria and the University of disciplines. Our impact factor was improve healthcare. Cantabria. over 1915 points in 2016. We have accumulated over 100,000 citations In partnership with prestigious IDIVAL encourages the development in international literature. institutions such as the Botín of knowledge. IDIVAL promotes Foundation,
Load more

Recommended publications
  • Recent Advances in Drosophila Models of Charcot-Marie-Tooth Disease
    International Journal of Molecular Sciences Review Recent Advances in Drosophila Models of Charcot-Marie-Tooth Disease Fukiko Kitani-Morii 1,2,* and Yu-ichi Noto 2 1 Department of Molecular Pathobiology of Brain Disease, Kyoto Prefectural University of Medicine, Kyoto 6028566, Japan 2 Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto 6028566, Japan; [email protected] * Correspondence: [email protected]; Tel.: +81-75-251-5793 Received: 31 August 2020; Accepted: 6 October 2020; Published: 8 October 2020 Abstract: Charcot-Marie-Tooth disease (CMT) is one of the most common inherited peripheral neuropathies. CMT patients typically show slowly progressive muscle weakness and sensory loss in a distal dominant pattern in childhood. The diagnosis of CMT is based on clinical symptoms, electrophysiological examinations, and genetic testing. Advances in genetic testing technology have revealed the genetic heterogeneity of CMT; more than 100 genes containing the disease causative mutations have been identified. Because a single genetic alteration in CMT leads to progressive neurodegeneration, studies of CMT patients and their respective models revealed the genotype-phenotype relationships of targeted genes. Conventionally, rodents and cell lines have often been used to study the pathogenesis of CMT. Recently, Drosophila has also attracted attention as a CMT model. In this review, we outline the clinical characteristics of CMT, describe the advantages and disadvantages of using Drosophila in CMT studies, and introduce recent advances in CMT research that successfully applied the use of Drosophila, in areas such as molecules associated with mitochondria, endosomes/lysosomes, transfer RNA, axonal transport, and glucose metabolism.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Kif1b Rab7a Lmna
    Title: Charcot-Marie-Tooth Neuropathy Type 2 GeneReview Molecular Genetics: Less Commonly Involved Genes Author: Bird TD Updated: March 2016 KIF1B Gene structure. KIF1B comprises 47 exons and 167.13 kb of DNA. Pathogenic allelic variants. See Table A, Locus Specific and HGMD Normal gene product. Kinesin-like protein KIF1B is involved in axonal transport of synaptic vesicle precursors [Zhao et al 2001]. The kinesin superfamily of proteins is essential for intracellular transport along microtubules. Abnormal gene product. There may be a defect in the transport of synaptic vesicles. RAB7A Gene structure. RAB7A has six exons and 87.9 kb of DNA. Pathogenic allelic variants. See Table A. Normal gene product. Ras-related protein Rab-7a belongs to the RAB family of Ras- related GTPases essential for the regulation of intracellular membrane trafficking. Rab- 7a is involved in transport between late endosomes and lysosomes. RAB-interacting lysosomal protein (RILP) induces the recruitment of dynein-dynactin motors and regulates transport toward the minus-end of microtubules [Verhoeven et al 2003]. Abnormal gene product. Abnormal Rab-7a may cause malfunction of lysosomes and inhibit neurite outgrowth [Spinosa et al 2008, Bucci & Deluca 2012]. LMNA Gene structure. LMNA has 12 exons spread over 24 kb of genomic DNA. Pathogenic allelic variants. The most common pathogenic variant found in individuals with CMT2B1 is p.Arg298Cys, a founder mutation in North Africa [Bouhouche et al 2007, De Sandre-Giovannoli et al 2002]. See also Table A. Table 5. Selected LMNA Variants DNA Nucleotide Protein Amino Acid Class of Variant Allele Reference Sequences Change Change Benign c.1908C>T p.= 1 c.398G>T p.Arg133Leu NM_170707.2 c.892C>T p.Arg298Cys Pathogenic NP_733821.1 c.1411C>T p.Arg471Cys c.1579C>T p.Arg527Cys Note on variant classification: Variants listed in the table have been provided by the author.
    [Show full text]
  • The Ubiquitin Proteasome System in Neuromuscular Disorders: Moving Beyond Movement
    International Journal of Molecular Sciences Review The Ubiquitin Proteasome System in Neuromuscular Disorders: Moving Beyond Movement 1, , 2, 3,4 Sara Bachiller * y , Isabel M. Alonso-Bellido y , Luis Miguel Real , Eva María Pérez-Villegas 5 , José Luis Venero 2 , Tomas Deierborg 1 , José Ángel Armengol 5 and Rocío Ruiz 2 1 Experimental Neuroinflammation Laboratory, Department of Experimental Medical Science, Lund University, Sölvegatan 19, 221 84 Lund, Sweden; [email protected] 2 Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia, Universidad de Sevilla/Instituto de Biomedicina de Sevilla-Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, 41012 Sevilla, Spain; [email protected] (I.M.A.-B.); [email protected] (J.L.V.); [email protected] (R.R.) 3 Unidad Clínica de Enfermedades Infecciosas, Hospital Universitario de Valme, 41014 Sevilla, Spain; [email protected] 4 Departamento de Especialidades Quirúrgicas, Bioquímica e Inmunología, Facultad de Medicina, 29071 Universidad de Málaga, Spain 5 Departamento de Fisiología, Anatomía y Biología Celular, Universidad Pablo de Olavide, 41013 Sevilla, Spain; [email protected] (E.M.P.-V.); [email protected] (J.Á.A.) * Correspondence: [email protected] These authors contributed equally to the work. y Received: 14 July 2020; Accepted: 31 August 2020; Published: 3 September 2020 Abstract: Neuromuscular disorders (NMDs) affect 1 in 3000 people worldwide. There are more than 150 different types of NMDs, where the common feature is the loss of muscle strength. These disorders are classified according to their neuroanatomical location, as motor neuron diseases, peripheral nerve diseases, neuromuscular junction diseases, and muscle diseases. Over the years, numerous studies have pointed to protein homeostasis as a crucial factor in the development of these fatal diseases.
    [Show full text]
  • Drosophila As a Model for Cmt Peripheral Neuropathy: Mutations in Trna Synthetases As an Example
    In: Drosophila Melanogaster Models of Motor Neuron Disease ISBN: 978-1-62618-747-4 Editor: Ruben J. Cauchi © 2013 Nova Science Publishers, Inc. No part of this digital document may be reproduced, stored in a retrieval system or transmitted commercially in any form or by any means. The publisher has taken reasonable care in the preparation of this digital document, but makes no expressed or implied warranty of any kind and assumes no responsibility for any errors or omissions. No liability is assumed for incidental or consequential damages in connection with or arising out of information contained herein. This digital document is sold with the clear understanding that the publisher is not engaged in rendering legal, medical or any other professional services. Chapter 5 DROSOPHILA AS A MODEL FOR CMT PERIPHERAL NEUROPATHY: MUTATIONS IN TRNA SYNTHETASES AS AN EXAMPLE Georg Steffes1 and Erik Storkebaum1,* 1Molecular Neurogenetics Laboratory, Max Planck Institute for Molecular Biomedicine, Muenster, Germany ABSTRACT Charcot-Marie-Tooth (CMT) disease is characterized by the degeneration of peripheral motor and sensory neurons, leading to progressive muscle weakness and wasting, and sensory loss. Electrophysiological and pathological criteria allow the distinction between demyelinating, axonal and intermediate forms of CMT. The disease is genetically heterogeneous, with currently more than 30 genes causally linked to CMT. The molecular underpinnings of the peripheral motor and sensory neuropathy are poorly understood, and there is no effective drug treatment available. In this chapter, we discuss the use of Drosophila melanogaster as a genetic model organism for CMT. Major advantages include the possibility to study the effect of CMT-associated mutant proteins on motor and sensory neurons in their physiological context, and its suitability to perform genetic screens.
    [Show full text]
  • Cracking the Monoubiquitin Code of Genetic Diseases
    International Journal of Molecular Sciences Review Cracking the Monoubiquitin Code of Genetic Diseases 1,2, 1,2, 1,2, Raj Nayan Sewduth y, Maria Francesca Baietti y and Anna A. Sablina * 1 VIB-KU Leuven Center for Cancer Biology, VIB, Herestraat 49, 3000 Leuven, Belgium; [email protected] (R.N.S.); [email protected] (M.F.B.) 2 Department of Oncology, KU Leuven, Herestraat 49, 3000 Leuven, Belgium * Correspondence: [email protected] These authors contributed equally to the work. y Received: 7 April 2020; Accepted: 23 April 2020; Published: 25 April 2020 Abstract: Ubiquitination is a versatile and dynamic post-translational modification in which single ubiquitin molecules or polyubiquitin chains are attached to target proteins, giving rise to mono- or poly-ubiquitination, respectively. The majority of research in the ubiquitin field focused on degradative polyubiquitination, whereas more recent studies uncovered the role of single ubiquitin modification in important physiological processes. Monoubiquitination can modulate the stability, subcellular localization, binding properties, and activity of the target proteins. Understanding the function of monoubiquitination in normal physiology and pathology has important therapeutic implications, as alterations in the monoubiquitin pathway are found in a broad range of genetic diseases. This review highlights a link between monoubiquitin signaling and the pathogenesis of genetic disorders. Keywords: ubiquitin system; genetic diseases; ubiquitin ligase; deubiquitinases; monoubiquitin signaling; vesicular trafficking; protein complex formation 1. Introduction Ubiquitination is a reversible post-translational modification process during which the highly conserved 76-aminoacid protein ubiquitin is conjugated to target proteins. Ubiquitin can be conjugated to a protein substrate via distinct mechanisms.
    [Show full text]
  • Charcot-Marie-Tooth Disease and Other Genetic Polyneuropathies
    Review Article 04/25/2018 on mAXWo3ZnzwrcFjDdvMDuzVysskaX4mZb8eYMgWVSPGPJOZ9l+mqFwgfuplwVY+jMyQlPQmIFeWtrhxj7jpeO+505hdQh14PDzV4LwkY42MCrzQCKIlw0d1O4YvrWMUvvHuYO4RRbviuuWR5DqyTbTk/icsrdbT0HfRYk7+ZAGvALtKGnuDXDohHaxFFu/7KNo26hIfzU/+BCy16w7w1bDw== by https://journals.lww.com/continuum from Downloaded Downloaded Address correspondence to Dr Sindhu Ramchandren, University of Michigan, from Charcot-Marie-Tooth Department of Neurology, https://journals.lww.com/continuum 2301 Commonwealth Blvd #1023, Ann Arbor, MI 48105, Disease and [email protected]. Relationship Disclosure: Dr Ramchandren has served Other Genetic on advisory boards for Biogen and Sarepta Therapeutics, by mAXWo3ZnzwrcFjDdvMDuzVysskaX4mZb8eYMgWVSPGPJOZ9l+mqFwgfuplwVY+jMyQlPQmIFeWtrhxj7jpeO+505hdQh14PDzV4LwkY42MCrzQCKIlw0d1O4YvrWMUvvHuYO4RRbviuuWR5DqyTbTk/icsrdbT0HfRYk7+ZAGvALtKGnuDXDohHaxFFu/7KNo26hIfzU/+BCy16w7w1bDw== Inc, and has received research/grant support from Polyneuropathies the Muscular Dystrophy Association (Foundation Sindhu Ramchandren, MD, MS Clinic Grant) and the National Institutes of Health (K23 NS072279). Unlabeled Use of ABSTRACT Products/Investigational Purpose of Review: Genetic polyneuropathies are rare and clinically heterogeneous. Use Disclosure: This article provides an overview of the clinical features, neurologic and electrodiagnostic Dr Ramchandren reports no disclosure. findings, and management strategies for Charcot-Marie-Tooth disease and other * 2017 American Academy genetic polyneuropathies as well as an algorithm for genetic testing. of Neurology.
    [Show full text]
  • Mutation in the Gene Encoding Ubiquitin Ligase LRSAM1 in Patients with Charcot-Marie-Tooth Disease
    Mutation in the Gene Encoding Ubiquitin Ligase LRSAM1 in Patients with Charcot-Marie-Tooth Disease Duane L. Guernsey1, Haiyan Jiang1, Karen Bedard1, Susan C. Evans1, Meghan Ferguson2, Makoto Matsuoka1, Christine Macgillivray1,3, Mathew Nightingale1, Scott Perry1, Andrea L. Rideout2, Andrew Orr3, Mark Ludman2,4, David L. Skidmore2,4, Timothy Benstead5, Mark E. Samuels1,6* 1 Department of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada, 2 Maritime Medical Genetics Service, Izaak Walton Killam Health Centre, Halifax, Nova Scotia, Canada, 3 Department of Ophthalmology and Visual Sciences, Dalhousie University, Halifax, Nova Scotia, Canada, 4 Department of Pediatrics, Division of Medical Genetics, Izaak Walton Killam Health Centre and Dalhousie University, Halifax, Nova Scotia, Canada, 5 Department of Medicine, Division of Neurology, Dalhousie University, Halifax, Nova Scotia, Canada, 6 Centre de Recherche de l’Hoˆpital Ste-Justine, Universite´ de Montre´al, Montre´al, Quebec, Canada Abstract Charcot-Marie-Tooth disease (CMT) represents a family of related sensorimotor neuropathies. We studied a large family from a rural eastern Canadian community, with multiple individuals suffering from a condition clinically most similar to autosomal recessive axonal CMT, or AR-CMT2. Homozygosity mapping with high-density SNP genotyping of six affected individuals from the family excluded 23 known genes for various subtypes of CMT and instead identified a single homozygous region on chromosome 9, at 122,423,730–129,841,977 Mbp, shared identical by state in all six affected individuals. A homozygous pathogenic variant was identified in the gene encoding leucine rich repeat and sterile alpha motif 1 (LRSAM1) by direct DNA sequencing of genes within the region in affected DNA samples.
    [Show full text]
  • Supplementary Data.Xlsx
    Electronic Supplementary Material (ESI) for Molecular BioSystems. This journal is © The Royal Society of Chemistry 2016 Average Average spectral spectral Fold UniProt IDGene Protein Name counts- counts- enrichm negative positive ent sample sample P12821 ACE HUMAN - ACE Angiotensin-converting enzyme 0 79.75 #DIV/0! Q71U36 TBA1A HUMAN - TUBA1A Tubulin alpha-1A chain 0 59.5 #DIV/0! P17812 PYRG1 HUMAN - CTPS1 CTP synthase 1 0 43.5 #DIV/0! P23921 RIR1 HUMAN - RRM1 Ribonucleoside-diphosphate reductase large subunit 0 35 #DIV/0! P49915GUAA HUMAN - GMPS GMP synthase 0 30.5 #DIV/0! P30153 2AAA HUMAN - PPP2R1A Serine/threonine-protein phosphatase 2A 65 kDa0 regulatory subunit29 A#DIV/0! alpha isoform P55786 PSA HUMAN - NPEPPS Puromycin-sensitive aminopeptidase 0 28.75 #DIV/0! O43143 DHX15 HUMAN - DHX15 Putative pre-mRNA-splicing factor ATP-dependent RNA0 helicase28.25 DHX15#DIV/0! P15170 ERF3A HUMAN - GSPT1 Eukaryotic peptide chain release factor GTP-binding0 subunit ERF3A24.75 #DIV/0! P09874PARP1HUMAN - PARP1 Poly 0 23.5 #DIV/0! Q9BXJ9 NAA15 HUMAN - NAA15 N-alpha-acetyltransferase 15, NatA auxiliary subunit0 23 #DIV/0! B0V043 B0V043 HUMAN - VARS Valyl-tRNA synthetase 0 20 #DIV/0! Q86VP6 CAND1 HUMAN - CAND1 Cullin-associated NEDD8-dissociated protein 1 0 19.5 #DIV/0! P04080CYTB HUMAN - CSTB Cystatin-B 0 19 #DIV/0! Q93009 UBP7 HUMAN - USP7 Ubiquitin carboxyl-terminal hydrolase 7 0 18 #DIV/0! Q9Y2L1 RRP44 HUMAN - DIS3 Exosome complex exonuclease RRP44 0 18 #DIV/0! Q13748 TBA3C HUMAN - TUBA3D Tubulin alpha-3C/D chain 0 18 #DIV/0! P29144 TPP2 HUMAN
    [Show full text]
  • Comparative Analysis of the Ubiquitin-Proteasome System in Homo Sapiens and Saccharomyces Cerevisiae
    Comparative Analysis of the Ubiquitin-proteasome system in Homo sapiens and Saccharomyces cerevisiae Inaugural-Dissertation zur Erlangung des Doktorgrades der Mathematisch-Naturwissenschaftlichen Fakultät der Universität zu Köln vorgelegt von Hartmut Scheel aus Rheinbach Köln, 2005 Berichterstatter: Prof. Dr. R. Jürgen Dohmen Prof. Dr. Thomas Langer Dr. Kay Hofmann Tag der mündlichen Prüfung: 18.07.2005 Zusammenfassung I Zusammenfassung Das Ubiquitin-Proteasom System (UPS) stellt den wichtigsten Abbauweg für intrazelluläre Proteine in eukaryotischen Zellen dar. Das abzubauende Protein wird zunächst über eine Enzym-Kaskade mit einer kovalent gebundenen Ubiquitinkette markiert. Anschließend wird das konjugierte Substrat vom Proteasom erkannt und proteolytisch gespalten. Ubiquitin besitzt eine Reihe von Homologen, die ebenfalls posttranslational an Proteine gekoppelt werden können, wie z.B. SUMO und NEDD8. Die hierbei verwendeten Aktivierungs- und Konjugations-Kaskaden sind vollständig analog zu der des Ubiquitin- Systems. Es ist charakteristisch für das UPS, daß sich die Vielzahl der daran beteiligten Proteine aus nur wenigen Proteinfamilien rekrutiert, die durch gemeinsame, funktionale Homologiedomänen gekennzeichnet sind. Einige dieser funktionalen Domänen sind auch in den Modifikations-Systemen der Ubiquitin-Homologen zu finden, jedoch verfügen diese Systeme zusätzlich über spezifische Domänentypen. Homologiedomänen lassen sich als mathematische Modelle in Form von Domänen- deskriptoren (Profile) beschreiben. Diese Deskriptoren können wiederum dazu verwendet werden, mit Hilfe geeigneter Verfahren eine gegebene Proteinsequenz auf das Vorliegen von entsprechenden Homologiedomänen zu untersuchen. Da die im UPS involvierten Homologie- domänen fast ausschließlich auf dieses System und seine Analoga beschränkt sind, können domänen-spezifische Profile zur Katalogisierung der UPS-relevanten Proteine einer Spezies verwendet werden. Auf dieser Basis können dann die entsprechenden UPS-Repertoires verschiedener Spezies miteinander verglichen werden.
    [Show full text]
  • Enrichment of Rare Variants in E3 Ubiquitin Ligase Genes in Early Onset Parkinson’S Disease
    Enrichment of Rare Variants in E3 Ubiquitin Ligase Genes in Early Onset Parkinson’s Disease Xiaojing Gu Sichuan University West China Hospital Yanbing Hou Sichuan University West China Hospital Yongping Chen Sichuan University West China Hospital Ruwei Ou Sichuan University West China Hospital Bei Cao Sichuan University West China Hospital Qianqian Wei Sichuan University West China Hospital Lingyu Zhang Sichuan University West China Hospital Wei Song Sichuan University West China Hospital Bi Zhao Sichuan University West China Hospital Ying Wu Sichuan University West China Hospital Chunyu Li Sichuan University West China Hospital Huifang Shang ( [email protected] ) West China Hospital of Sichuan University https://orcid.org/0000-0003-0947-1151 Research Keywords: E3 ubiquitin ligase, Early onset Parkinson’s disease, burden, association Posted Date: March 3rd, 2021 DOI: https://doi.org/10.21203/rs.3.rs-262042/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/14 Abstract Background Dysfunction of the ubiquitination proteasome system (UPS) is important in the pathogenesis of Parkinson’s disease (PD). Patients with early onset PD (EOPD) are more susceptible to genetic factors. We systematically examined the overlaps between E3 ubiquitin ligase genes and EOPD. Methods A total of 695 EOPD patients were sequenced with whole exome sequencing. Aggregate burden for rare variants (Minor allele frequency <0.001 and <0.0001) in a total of 44 E3 ubiquitin ligase genes causing disorders involved in the nervous system were analyzed. Results There was signicant enrichment of the rare and rare damaging variants in the E3 ubiquitin ligase genes in EOPD patients.
    [Show full text]
  • Targeted Next-Generation Sequencing Panels in the Diagnosis of Charcot-Marie-Tooth Disease
    ARTICLE OPEN ACCESS Targeted next-generation sequencing panels in the diagnosis of Charcot-Marie-Tooth disease Andrea Cortese, MD, PhD, Janel E. Wilcox, MS, CGC, James M. Polke, PhD, Roy Poh, PhD, Correspondence Mariola Skorupinska, MA, Alexander M. Rossor, FRCP, PhD, Matilde Laura, MD, Pedro J. Tomaselli, MD, Dr. Reilly Henry Houlden, MD, PhD, Michael E. Shy, MD, and Mary M. Reilly, MD, FRCPI, FRCP [email protected] Neurology® 2020;94:e51-e61. doi:10.1212/WNL.0000000000008672 Abstract MORE ONLINE Objective Podcast To investigate the effectiveness of targeted next-generation sequencing (NGS) panels in Dr. Michelle Mauermann achieving a molecular diagnosis in Charcot-Marie-Tooth disease (CMT) and related disorders talks with Dr. Mary Reilly about her paper on targeted in a clinical setting. next-generation sequencing panels in the diagnosis of Methods Charcot-Marie-Tooth We prospectively enrolled 220 patients from 2 tertiary referral centers, one in London, United disease. Kingdom (n = 120), and one in Iowa (n = 100), in whom a targeted CMT NGS panel had been NPub.org/wkykkn requested as a diagnostic test. PMP22 duplication/deletion was previously excluded in de- myelinating cases. We reviewed the genetic and clinical data upon completion of the diagnostic process. Results After targeted NGS sequencing, a definite molecular diagnosis, defined as a pathogenic or likely pathogenic variant, was reached in 30% of cases (n = 67). The diagnostic rate was similar in London (32%) and Iowa (29%). Variants of unknown significance were found in an additional 33% of cases. Mutations in GJB1, MFN2, and MPZ accounted for 39% of cases that received genetic confirmation, while the remainder of positive cases had mutations in diverse genes, including SH3TC2, GDAP1, IGHMBP2, LRSAM1, FDG4, and GARS, and another 12 less common genes.
    [Show full text]